Short answer
MapLight Therapeutics, Inc. (MPLT) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$60M
- +0.8% QoQ
- EPS (diluted)
- −$1.32
- +1.5% QoQ
Source: XBRL data from the MapLight Therapeutics, Inc. (MPLT) Q2 2026 10-Q on SEC EDGAR. USD.
MapLight Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered lease risk: South San Francisco facility expected to commence in May 2027, subject to landlord tenant improvements
- Most materially updated operational risk: Redwood City lease termination moved expiration from June 2031 to September 2027
- Regulatory risk: ML-007C-MA requires multiple clinical trials and regulatory approval before commercialization
- Near-term performance risk: Research and development expense increased to $107.1 million from $46.6 million year-to-date
- Liquidity risk: Accumulated deficit reached $481.4 million, with additional capital required despite $351.3 million available funding runway beyond twelve months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MapLight Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.